


## hSMG-1 inhibitor 11e

<b>Cat. No.:</b>	HY-124760
<b>CAS No.:</b>	1402452-10-1
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>27</sub> N <sub>7</sub> O <sub>3</sub> S
<b>Molecular Weight:</b>	517.6
<b>Target:</b>	mTOR; PI3K; CDK
<b>Pathway:</b>	PI3K/Akt/mTOR; Cell Cycle/DNA Damage
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 50 mg/mL (96.60 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		1.9320 mL	9.6600 mL	19.3199 mL
		<b>5 mM</b>		0.3864 mL	1.9320 mL	3.8640 mL
	<b>10 mM</b>		0.1932 mL	0.9660 mL	1.9320 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (9.66 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 5 mg/mL (9.66 mM); Suspended solution; Need ultrasonic					

### BIOLOGICAL ACTIVITY

<b>Description</b>	hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC <sub>50</sub> of <0.05 nM. hSMG-1 inhibitor 11e shows >900-fold selectivity over mTOR (IC <sub>50</sub> of 45 nM), PI3Kα/γ (IC <sub>50</sub> s of 61 nM and 92 nM) and CDK1/CDK2 (IC <sub>50</sub> s of 32 μM and 7.1 μM) <sup>[1]</sup> .			
<b>IC<sub>50</sub> &amp; Target</b>	hSMG-1 <0.05 nM (IC <sub>50</sub> )	mTOR 45 nM (IC <sub>50</sub> )	PI3Kα 61 nM (IC <sub>50</sub> )	PI3Kγ 92 nM (IC <sub>50</sub> )
	CDK1 32 μM (IC <sub>50</sub> )	CDK2 7.1 μM (IC <sub>50</sub> )		
<b>In Vitro</b>	hSMG-1 kinase plays a dual role in a highly conserved RNA surveillance pathway termed nonsense-mediated RNA decay			

---

(NMD) and in cellular genotoxic stress response. Since deregulation of cellular responses to stress contributes to tumor growth and resistance to chemotherapy, hSMG-1 is a potential target for cancer treatment<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Ariamala Gopalsamy, et al. Identification of pyrimidine derivatives as hSMG-1 inhibitors. Bioorg Med Chem Lett. 2012 Nov 1;22(21):6636-41.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA